By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


AM-Pharma Holding BV 

Rumpsterweg 6
3720 AE
Bunnik    3981 AK  The Netherlands
Phone: 31-0-30-2289222 Fax: 31-0-30-2289220


Company News
AM-Pharma Completes Patient Recruitment Of Recombinant Human Alkaline Phosphatase (recAP) Phase II Trial In Acute Kidney Injury 5/22/2017 6:18:43 AM
AM-Pharma Publishes Safety And Pharmacokinetic Data From Phase I recAP Trial 5/10/2016 10:41:30 AM
AM-Pharma Receives FDA Fast Track Designation For Recap In Acute Kidney Injury 4/26/2016 10:38:48 AM
AM-Pharma Publishes Further Preclinical Data On recAP To Treat Acute Kidney Injury 9/30/2015 10:27:42 AM
AM-Pharma Receives FDA And European Medicines Agency Orphan Drug Designation To Treat Hypophosphatasia 6/9/2015 9:46:01 AM
Pfizer (PFE) Pays $87.5 Million for Stake in AM-Pharma, With Option to Swallow Entire Company 5/11/2015 4:05:58 PM
Preclinical Data Published On AM-Pharma Holding BV’s recAP To Treat Ultra Rare Disease Hypophosphatasia 12/2/2014 8:51:49 AM
AM-Pharma Holding BV Presents Preclinical Data On Mode-Of-Action For recAP In Acute Kidney Injury At American Society of Nephrology Meeting 11/13/2014 11:29:31 AM
AM-Pharma Holding BV Locks In €12.2 Million Financing Round 9/11/2014 6:28:43 AM
AM-Pharma Holding BV Announces Positive Phase I Data On recAP, For Acute Kidney Injury 3/26/2014 9:47:42 AM